Search results

1. Another false dawn for p53

   … presence KT-253* Kymera Ph1 data at ASCO 2024; Kymera no longer active in oncology …

   
    

   Jacob Plieth
    
   - 04/16/2025 - 10:14

2. AACR 2025 preview – distressed biotechs seek redemption

   … CT038 Ph1 +/- toripalimab Had monoRx data at ASCO 2024 29 April clinical trials minisymposium …

   
    

   Jacob Plieth
    
   - 03/28/2025 - 08:55

3. AACR 2025 preview – Roche's TIGIT postmortem

   … AffyImmune CT206 Ph1 thyroid cancers Had ASCO 2024 data   Merck had more success with …

   
    

   Jacob Plieth
    
   - 04/04/2025 - 13:32

4. ELCC 2025 – AstraZeneca gets a survival boost from Laura

   … in stage III EGFRm NSCLC   ELCC 2025 ASCO 2024 Data maturity 31% 20% … HR=0.81; CI 0.42-1.56 Source: ELCC 2025 & ASCO 2024. Conferences Trial …

   
    

   Madeleine Armstrong
    
   - 03/26/2025 - 08:17

5. Aadi gets an ADC makeover

   … Only ADC in clinic is AbbVie’s ABBV-706 ( early data at ASCO 2024 ) Source: OncologyPipeline & company …

   
    

   Madeleine Armstrong
    
   - 03/20/2025 - 15:37

6. Make or break time for Caribou

   … disappointed with its allogeneic Car-T project CB-010 at ASCO 2024 , will soon have a chance to redeem itself. In … 14.8mth Note: *2L LBCLC subgroup. Source: ASCO 2024 & product labels.   Caribou has therefore …

   
    

   Madeleine Armstrong
    
   - 03/25/2025 - 15:35

7. Zymeworks follows Mersana

   … M7152 Merck KGaA Preclinical, disclosed at ASCO 2024 investor event Undisclosed ADC …

   
    

   Jacob Plieth
    
   - 10/01/2025 - 11:55

8. KAT6 catalysts to kick off 2025

   … with Faslodex, and monotherapy data were last reported at ASCO 2024, showing an 11% ORR . The good news is that …

   
    

   Jacob Plieth
    
   - 01/08/2025 - 13:52

9. Affimed needs more time with AFM24

   … of AFM24 + Tecentriq in relapsed NSCLC   ASCO 2024 + Jun 2024 PR Dec 2024 PR …

   
    

   Madeleine Armstrong
    
   - 12/18/2024 - 15:56

10. Triple meeting 2024 – Zai Lab impresses in small cell

    … Presentation venue Triple meeting 2024 ESMO 2023 ASCO 2024 ORR 74% (14/19)* 40% (40/99) …

    
     

    Madeleine Armstrong
     
    - 10/29/2024 - 13:27